Grant of award shares under the restricted share award scheme
Filed with HKEX · Stock code 9966 · · 3 pages · English
Summary by 6ix AI
Alphamab Oncology has announced the grant of award shares under its Restricted Share Award Scheme. The purpose of this grant is to recognize contributions, motivate retention, and align interests between the company and the grantee.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Alphamab Oncology
- Voluntary announcement - latest research updates of JSKN003 presented at the 2026 ESMO congress
- Voluntary announcement - results of a phase I/II clinical study of JSKN033 in patients with CC following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
- Voluntary announcement - latest research results of two phase III clinical studies of anbenitamab (KN026) were presented at the 2026 ESMO Congress as lba oral presentations
- Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.
- Next Day Disclosure Return
Later from Alphamab Oncology
- Voluntary announcement - first patient dosed in phase III clinical study of JSKN033 monotherapy for the treatment of cervical cancer
- Supplementary announcement on discloseable transaction
- Voluntary announcement - IND approval by the FDA for a phase I clinical study of JSKN021
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - appointment of chief financial officer
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology